REPLIMUNE GROUP, INC. Operating Expenses
REPLIMUNE GROUP, INC. (REPL) reported Operating Expenses of $68.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- REPLIMUNE GROUP, INC. operating expenses for the quarter ending 2026-06-30 was $68.25M, a 24.52% decline year-over-year.
- REPLIMUNE GROUP, INC. operating expenses for the quarter ending 2026-03-31 was $73.34M, a 7.55% decline year-over-year.
- REPLIMUNE GROUP, INC. operating expenses for the quarter ending 2025-12-31 was $71.87M, a 8.86% increase year-over-year.
- REPLIMUNE GROUP, INC. operating expenses for the quarter ending 2025-09-30 was $84.29M, a 43.07% increase year-over-year.
- REPLIMUNE GROUP, INC. operating expenses for fiscal 2026 was $319.92M, a 22.28% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. operating expenses for fiscal 2025 was $261.63M, a 11.44% increase from fiscal 2024.
- REPLIMUNE GROUP, INC. operating expenses for fiscal 2024 was $234.77M, a 32.58% increase from fiscal 2023.
- REPLIMUNE GROUP, INC. operating expenses for fiscal 2023 was $177.08M, a 49.67% increase from fiscal 2022.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $68.25M 10-Q · filed 2026-08-14 | $141.59M derived: sum of 2 quarters · filed 2026-08-14 | $213.45M derived: sum of 3 quarters · filed 2026-08-14 | $297.74M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $73.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $145.21M derived: sum of 2 quarters · filed 2026-06-29 | $229.50M derived: sum of 3 quarters · filed 2026-06-29 | $319.92M 10-K · filed 2026-06-29 | |
| 2025-12-31 | $71.87M 10-Q · filed 2026-02-03 | $156.16M derived: sum of 2 quarters · filed 2026-02-03 | $246.58M 10-Q · filed 2026-02-03 | $325.91M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-09-30 | $84.29M 10-Q · filed 2025-11-06 | $174.72M 10-Q · filed 2025-11-06 | $254.04M derived: sum of 3 quarters · filed 2026-08-14 | $320.06M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $90.42M 10-Q · filed 2026-08-14 | $169.75M derived: sum of 2 quarters · filed 2026-08-14 | $235.77M derived: sum of 3 quarters · filed 2026-08-14 | $294.69M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $79.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $145.35M derived: sum of 2 quarters · filed 2026-06-29 | $204.26M derived: sum of 3 quarters · filed 2026-06-29 | $261.63M 10-K · filed 2026-06-29 | |
| 2024-12-31 | $66.02M 10-Q · filed 2026-02-03 | $124.94M derived: sum of 2 quarters · filed 2026-02-03 | $182.30M 10-Q · filed 2026-02-03 | $241.06M derived: sum of 4 quarters · filed 2026-02-03 | |
| 2024-09-30 | $58.92M 10-Q · filed 2025-11-06 | $116.28M 10-Q · filed 2025-11-06 | $175.04M derived: sum of 3 quarters · filed 2025-11-06 | $231.58M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $57.37M 10-Q · filed 2025-08-07 | $116.12M derived: sum of 2 quarters · filed 2025-08-07 | $172.66M derived: sum of 3 quarters · filed 2025-08-07 | $236.49M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $58.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | $115.30M derived: sum of 2 quarters · filed 2025-05-22 | $179.13M derived: sum of 3 quarters · filed 2025-05-22 | $234.77M 10-K · filed 2025-05-22 | |
| 2023-12-31 | $56.54M 10-Q · filed 2025-02-12 | $120.37M derived: sum of 2 quarters · filed 2025-02-12 | $176.02M 10-Q · filed 2025-02-12 | $229.01M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-09-30 | $63.83M 10-Q · filed 2024-11-12 | $119.48M 10-Q · filed 2024-11-12 | $172.47M derived: sum of 3 quarters · filed 2024-11-12 | $214.10M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $55.65M 10-Q · filed 2024-08-08 | $108.64M derived: sum of 2 quarters · filed 2024-08-08 | $150.27M derived: sum of 3 quarters · filed 2024-08-08 | $191.85M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $52.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | $94.63M derived: sum of 2 quarters · filed 2024-05-16 | $136.20M derived: sum of 3 quarters · filed 2024-05-16 | $177.08M 10-K · filed 2024-05-16 | |
| 2022-12-31 | $41.63M 10-Q · filed 2024-02-08 | $83.21M derived: sum of 2 quarters · filed 2024-02-08 | $124.08M 10-Q · filed 2024-02-08 | $156.07M derived: sum of 4 quarters · filed 2024-02-08 | |
| 2022-09-30 | $41.58M 10-Q · filed 2023-11-07 | $82.45M 10-Q · filed 2023-11-07 | $114.44M derived: sum of 3 quarters · filed 2023-11-07 | $144.14M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $40.88M 10-Q · filed 2023-08-03 | $72.86M derived: sum of 2 quarters · filed 2023-08-03 | $102.56M derived: sum of 3 quarters · filed 2023-08-03 | $131.81M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $31.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | $61.69M derived: sum of 2 quarters · filed 2023-05-18 | $90.93M derived: sum of 3 quarters · filed 2023-05-18 | $118.31M 10-K · filed 2023-05-18 | |
| 2021-12-31 | $29.70M 10-Q · filed 2023-02-09 | $58.95M derived: sum of 2 quarters · filed 2023-02-09 | $86.33M 10-Q · filed 2023-02-09 | $108.51M derived: sum of 4 quarters · filed 2023-02-09 | |
| 2021-09-30 | $29.25M 10-Q · filed 2022-11-03 | $56.63M 10-Q · filed 2022-11-03 | $78.81M derived: sum of 3 quarters · filed 2022-11-03 | $99.09M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $27.38M 10-Q · filed 2022-08-04 | $49.56M derived: sum of 2 quarters · filed 2022-08-04 | $69.84M derived: sum of 3 quarters · filed 2022-08-04 | $89.50M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $22.18M 10-K · filed 2021-05-20 | $42.46M derived: sum of 2 quarters · filed 2022-02-03 | $62.12M derived: sum of 3 quarters · filed 2022-02-03 | $79.95M 10-K · filed 2022-05-19 | |
| 2020-12-31 | $20.27M 10-Q · filed 2022-02-03 | $39.94M derived: sum of 2 quarters · filed 2022-02-03 | $57.77M 10-Q · filed 2022-02-03 | $74.16M derived: sum of 4 quarters · filed 2022-02-03 | |
| 2020-09-30 | $19.66M 10-Q · filed 2021-11-04 | $37.50M 10-Q · filed 2021-11-04 | $53.88M derived: sum of 3 quarters · filed 2021-11-04 | $70.55M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $17.83M 10-Q · filed 2021-08-06 | $34.22M derived: sum of 2 quarters · filed 2021-08-06 | $50.88M derived: sum of 3 quarters · filed 2021-08-06 | $63.12M derived: sum of 4 quarters · filed 2021-08-06 | |
| 2020-03-31 | $16.39M 10-K · filed 2021-05-20 | $33.05M derived: sum of 2 quarters · filed 2021-05-20 | $45.29M derived: sum of 3 quarters · filed 2021-05-20 | $56.20M 10-K · filed 2021-05-20 | |
| 2019-12-31 | $16.66M 10-K · filed 2021-05-20 | $28.91M derived: sum of 2 quarters · filed 2021-05-20 | $39.81M 10-Q · filed 2021-02-04 | $47.64M derived: sum of 4 quarters · filed 2021-05-20 | |
| 2019-09-30 | $12.24M 10-K · filed 2021-05-20 | $23.15M 10-Q · filed 2020-11-05 | $30.98M derived: sum of 3 quarters · filed 2021-05-20 | $41.11M derived: sum of 4 quarters · filed 2021-05-20 | |
| 2019-06-30 | $10.91M 10-K · filed 2021-05-20 | $18.73M derived: sum of 2 quarters · filed 2021-05-20 | $28.87M derived: sum of 3 quarters · filed 2021-05-20 | $35.97M derived: sum of 4 quarters · filed 2021-05-20 | |
| 2019-03-31 | $7.83M 10-K · filed 2020-06-03 | $7.83M 10-K · filed 2019-06-28 | $17.96M derived: sum of 2 quarters · filed 2020-06-03 | $25.07M derived: sum of 3 quarters · filed 2020-06-03 | $30.95M 10-K · filed 2020-06-03 |
| 2018-12-31 | $10.14M 10-K · filed 2020-06-03 | $17.24M derived: sum of 2 quarters · filed 2020-06-03 | $23.12M 10-Q · filed 2020-02-13 | $30.18M derived: sum of 4 quarters · filed 2020-06-03 | |
| 2018-09-30 | $7.10M 10-K · filed 2020-06-03 | $12.98M 10-Q · filed 2019-11-12 | $20.05M derived: sum of 3 quarters · filed 2020-06-03 | $24.78M derived: sum of 4 quarters · filed 2020-06-03 | |
| 2018-06-30 | $5.88M 10-K · filed 2020-06-03 | $12.94M derived: sum of 2 quarters · filed 2020-06-03 | $17.68M derived: sum of 3 quarters · filed 2020-06-03 | $21.93M derived: sum of 4 quarters · filed 2020-06-03 | |
| 2018-03-31 | $7.07M 10-K · filed 2019-06-28 | $11.80M derived: sum of 2 quarters · filed 2019-06-28 | $16.05M derived: sum of 3 quarters · filed 2019-06-28 | $19.23M 10-K · filed 2020-06-03 | |
| 2017-12-31 | $4.73M 10-K · filed 2019-06-28 | $8.99M derived: sum of 2 quarters · filed 2019-06-28 | $12.16M 10-Q · filed 2019-02-14 | ||
| 2017-09-30 | $4.26M 10-K · filed 2019-06-28 | $7.43M 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | $3.18M 10-K · filed 2019-06-28 | ||||
| 2017-03-31 | $9.65M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |